Valneva's Stock Rises Following Oddo BHF's Target Upgrade

Analyst Confidence Boosts Valneva's Prospects

Oddo BHF reaffirmed its 'outperform' recommendation on Valneva's stock this morning, while raising its price target from 7 to 8 euros. This new target implies an appreciation potential of about 99% compared to the last traded price, reflecting the analyst's confidence in the commercial prospects of the group. The broker is not alone in its positive view: Stifel has maintained a buy recommendation since early January with a target of 10 euros, suggesting an even greater margin for growth. These optimistic stances from research offices support the stock's rise, which now shows an annual performance of 50.67%, after a three-month increase of 3.34%. The upward movement this Wednesday occurs as the stock trades above its 50-day moving average, positioned at 3.93 euros, indicating a favorable short-term technical momentum.

Renewed Interest in Valneva Following Pilot Vaccination Strategy Announcement

The renewed interest in Valneva comes in the wake of the announcement of a pilot vaccination strategy conducted jointly with Instituto Butantan in Brazil. This initiative involves IXCHIQ®, the single-dose vaccine developed by the French laboratory against chikungunya. The campaign will serve as a basis for the post-commercialization studies required after the product's approval, thus enhancing the prospects for deployment in a region heavily exposed to this vector-borne disease. This strategic partnership illustrates Valneva's ability to forge major institutional alliances to accelerate the penetration of its vaccine solutions in emerging markets. Technically, crossing the 200-day moving average, established at 3.60 euros, indicates a fundamental recovery of the stock after a period of consolidation. Despite a high monthly volatility of 13.70%, the stock's trajectory remains positive, supported by the commitment of institutional investors.